A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections

Anasuya Chattopadhyay, Patricia Aguilar, Nathen E. Bopp, Timur O. Yarovinsky, Scott Weaver, John K. Rose

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Chikungunya virus (CHIKV) and Zika virus (ZIKV) have recently expanded their range in the world and caused serious and widespread outbreaks of near pandemic proportions. There are no licensed vaccines that protect against these co-circulating viruses that are transmitted by invasive mosquito vectors. We report here on the development of a single-dose, bivalent experimental vaccine for CHIKV and ZIKV. This vaccine is based on a chimeric vesicular stomatitis virus (VSV) that expresses the CHIKV envelope polyprotein (E3-E2-6K-E1) in place of the VSV glycoprotein (G) and also expresses the membrane-envelope (ME) glycoproteins of ZIKV. This vaccine induced neutralizing antibody responses to both CHIKV and ZIKV in wild-type mice and in interferon receptor-deficient A129 mice, animal models for CHIKV and ZIKV infection. A single vaccination of A129 mice with the vector protected these mice against infection with both CHIKV and ZIKV. Our single-dose vaccine could provide durable, low-cost protection against both CHIKV and ZIKV for people traveling to or living in areas where both viruses are circulating, which include most tropical regions in the world.

Original languageEnglish (US)
JournalVaccine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Zika virus
Chikungunya virus
Synthetic Vaccines
vaccines
Viruses
viruses
Vaccines
infection
Vesiculovirus
Vesicular Stomatitis
mice
glycoproteins
Interferon Receptors
Polyproteins
Membrane Glycoproteins
Pandemics
pandemic
interferons
dosage
Zika Virus Infection

Keywords

  • Arbovirus
  • Microcephaly
  • Vesicular stomatitis virus

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections. / Chattopadhyay, Anasuya; Aguilar, Patricia; Bopp, Nathen E.; Yarovinsky, Timur O.; Weaver, Scott; Rose, John K.

In: Vaccine, 01.01.2018.

Research output: Contribution to journalArticle

Chattopadhyay, Anasuya ; Aguilar, Patricia ; Bopp, Nathen E. ; Yarovinsky, Timur O. ; Weaver, Scott ; Rose, John K. / A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections. In: Vaccine. 2018.
@article{b7100e8412d440f9a53199fe3daebcb3,
title = "A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections",
abstract = "Chikungunya virus (CHIKV) and Zika virus (ZIKV) have recently expanded their range in the world and caused serious and widespread outbreaks of near pandemic proportions. There are no licensed vaccines that protect against these co-circulating viruses that are transmitted by invasive mosquito vectors. We report here on the development of a single-dose, bivalent experimental vaccine for CHIKV and ZIKV. This vaccine is based on a chimeric vesicular stomatitis virus (VSV) that expresses the CHIKV envelope polyprotein (E3-E2-6K-E1) in place of the VSV glycoprotein (G) and also expresses the membrane-envelope (ME) glycoproteins of ZIKV. This vaccine induced neutralizing antibody responses to both CHIKV and ZIKV in wild-type mice and in interferon receptor-deficient A129 mice, animal models for CHIKV and ZIKV infection. A single vaccination of A129 mice with the vector protected these mice against infection with both CHIKV and ZIKV. Our single-dose vaccine could provide durable, low-cost protection against both CHIKV and ZIKV for people traveling to or living in areas where both viruses are circulating, which include most tropical regions in the world.",
keywords = "Arbovirus, Microcephaly, Vesicular stomatitis virus",
author = "Anasuya Chattopadhyay and Patricia Aguilar and Bopp, {Nathen E.} and Yarovinsky, {Timur O.} and Scott Weaver and Rose, {John K.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.vaccine.2018.05.095",
language = "English (US)",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections

AU - Chattopadhyay, Anasuya

AU - Aguilar, Patricia

AU - Bopp, Nathen E.

AU - Yarovinsky, Timur O.

AU - Weaver, Scott

AU - Rose, John K.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Chikungunya virus (CHIKV) and Zika virus (ZIKV) have recently expanded their range in the world and caused serious and widespread outbreaks of near pandemic proportions. There are no licensed vaccines that protect against these co-circulating viruses that are transmitted by invasive mosquito vectors. We report here on the development of a single-dose, bivalent experimental vaccine for CHIKV and ZIKV. This vaccine is based on a chimeric vesicular stomatitis virus (VSV) that expresses the CHIKV envelope polyprotein (E3-E2-6K-E1) in place of the VSV glycoprotein (G) and also expresses the membrane-envelope (ME) glycoproteins of ZIKV. This vaccine induced neutralizing antibody responses to both CHIKV and ZIKV in wild-type mice and in interferon receptor-deficient A129 mice, animal models for CHIKV and ZIKV infection. A single vaccination of A129 mice with the vector protected these mice against infection with both CHIKV and ZIKV. Our single-dose vaccine could provide durable, low-cost protection against both CHIKV and ZIKV for people traveling to or living in areas where both viruses are circulating, which include most tropical regions in the world.

AB - Chikungunya virus (CHIKV) and Zika virus (ZIKV) have recently expanded their range in the world and caused serious and widespread outbreaks of near pandemic proportions. There are no licensed vaccines that protect against these co-circulating viruses that are transmitted by invasive mosquito vectors. We report here on the development of a single-dose, bivalent experimental vaccine for CHIKV and ZIKV. This vaccine is based on a chimeric vesicular stomatitis virus (VSV) that expresses the CHIKV envelope polyprotein (E3-E2-6K-E1) in place of the VSV glycoprotein (G) and also expresses the membrane-envelope (ME) glycoproteins of ZIKV. This vaccine induced neutralizing antibody responses to both CHIKV and ZIKV in wild-type mice and in interferon receptor-deficient A129 mice, animal models for CHIKV and ZIKV infection. A single vaccination of A129 mice with the vector protected these mice against infection with both CHIKV and ZIKV. Our single-dose vaccine could provide durable, low-cost protection against both CHIKV and ZIKV for people traveling to or living in areas where both viruses are circulating, which include most tropical regions in the world.

KW - Arbovirus

KW - Microcephaly

KW - Vesicular stomatitis virus

UR - http://www.scopus.com/inward/record.url?scp=85047385669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047385669&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2018.05.095

DO - 10.1016/j.vaccine.2018.05.095

M3 - Article

C2 - 29807712

AN - SCOPUS:85047385669

JO - Vaccine

JF - Vaccine

SN - 0264-410X

ER -